7. Haematological Disorders: A Complete Guide to Iron Deficiency Anaemia and Megaloblastic Anaemia

HAEMATOLOGICAL DISORDERS AND PHARMACOTHERAPY

Welcome, future pharmacists and healthcare professionals!

As a pharmacotherapeutics educator with years of experience teaching haematology, I have observed that anaemia is one of the most common conditions encountered in clinical practice worldwide. Haematological disorders affect the blood and its components, including red blood cells, white blood cells, platelets, and bone marrow. Among these, anaemia is the most prevalent, affecting approximately one-quarter of the global population. Iron deficiency anaemia and megaloblastic anaemia are two of the most common types, yet they are often underdiagnosed or mismanaged.

In this comprehensive guide, I will take you through two major haematological disorders: Iron Deficiency Anaemia and Megaloblastic Anaemia. We will explore their pathophysiology, causes, symptoms, diagnostic approaches, and evidence-based pharmacotherapy and non-pharmacological management strategies. By the end of this article, you will have the knowledge and confidence to counsel patients effectively, recognize red flags, and contribute to better haematological health outcomes. Let us begin.

PART 1: IRON DEFICIENCY ANAEMIA (IDA)

What is Iron Deficiency Anaemia?

Iron deficiency anaemia (IDA) is a condition that occurs when the body lacks sufficient iron to produce haemoglobin, the protein in red blood cells responsible for transporting oxygen from the lungs to the rest of the body. Haemoglobin gives blood its red colour and is essential for cellular respiration. When iron stores are depleted, the body produces fewer and smaller red blood cells, leading to reduced oxygen delivery to tissues and organs.

IDA is the most common type of anaemia worldwide, affecting approximately 1.6 billion people globally. It is particularly prevalent in women of reproductive age, children, and pregnant women. The condition can be caused by inadequate dietary intake, increased iron requirements, chronic blood loss, or impaired iron absorption. If left untreated, IDA can lead to significant morbidity, including fatigue, cognitive impairment, and reduced work capacity.

Causes of Iron Deficiency Anaemia

Iron deficiency anaemia can result from several mechanisms:

• Chronic blood loss: The most common cause in adults, including menstrual bleeding in women, gastrointestinal bleeding from ulcers, colorectal cancer, or inflammatory bowel disease.
• Inadequate dietary intake: Diets low in iron, particularly in developing countries or in individuals with poor nutritional habits.
• Increased iron requirements: During periods of rapid growth (infancy, adolescence) or pregnancy, when iron demands exceed dietary intake.
• Malabsorption: Conditions such as coeliac disease, gastric bypass surgery, or chronic diarrhoea can impair iron absorption in the gastrointestinal tract.

Symptoms of Iron Deficiency Anaemia

The symptoms of IDA can vary depending on the severity and duration of the deficiency. Common symptoms include:

• Fatigue and weakness: The most common symptom due to reduced oxygen delivery to tissues
• Pale skin and mucosal membranes (pallor)
• Shortness of breath (dyspnoea) and palpitations
• Dizziness and light-headedness
• Brittle nails, koilonychia (spoon-shaped nails)
• Cold hands and feet
• Hair loss and dry skin
• Pica: Cravings for non-food items such as ice, clay, or dirt

Diagnosis of Iron Deficiency Anaemia

Diagnosis of IDA is based on clinical presentation and laboratory findings:

• Complete blood count (CBC): Shows low haemoglobin and haematocrit, microcytic (small) and hypochromic (pale) red blood cells.
• Serum ferritin: A low serum ferritin level (< 30 ng/mL) is highly specific for iron deficiency.
• Serum iron and total iron-binding capacity (TIBC): Low serum iron with high TIBC indicates iron deficiency.
• Transferrin saturation: < 20% suggests iron deficiency.

Management of Iron Deficiency Anaemia

Non-Pharmacological Management

Non-pharmacological interventions are essential for preventing and managing IDA:

• Iron-rich diet: Encouraging consumption of heme iron (red meat, poultry, fish) and non-heme iron (beans, lentils, dark leafy greens, fortified cereals).
• Vitamin C supplementation: Enhances non-heme iron absorption. Encouraging consumption of citrus fruits, tomatoes, and bell peppers with iron-rich meals.
• Avoiding inhibitors: Tea, coffee, and calcium supplements can inhibit iron absorption and should be taken separately from iron-rich meals.
• Addressing underlying causes: Treating sources of chronic blood loss (menorrhagia, peptic ulcer disease).

Pharmacological Management

Pharmacological treatment of IDA focuses on replenishing iron stores:

• Oral iron supplements: Ferrous sulfate is the most commonly used and cost-effective oral iron supplement. Other forms include ferrous gluconate and ferrous fumarate.
• Dosing: Standard dose is 100-200 mg of elemental iron daily. It should be taken on an empty stomach for optimal absorption, but can be taken with food if gastrointestinal side effects occur.
• Side effects: Gastrointestinal side effects include nausea, constipation, and dark stools. Starting with a lower dose and gradually increasing can improve tolerance.
• Intravenous iron: Used for patients who cannot tolerate oral iron, have severe anaemia, or have malabsorption issues. Common forms include iron sucrose and ferric carboxymaltose.
• Response monitoring: Haemoglobin levels typically rise within 2-4 weeks. Iron therapy should continue for at least 3-6 months to replenish iron stores (normalization of ferritin).

PART 2: MEGALOBLASTIC ANAEMIA

What is Megaloblastic Anaemia?

Megaloblastic anaemia is a type of anaemia caused by a deficiency of vitamin B12 (cobalamin) or folic acid (folate). These vitamins are essential for DNA synthesis and red blood cell production. When there is a deficiency, red blood cells become abnormally large (macrocytic) and immature (megaloblasts) in the bone marrow, leading to ineffective erythropoiesis and reduced red blood cell count.

Megaloblastic anaemia is less common than iron deficiency anaemia but has significant clinical implications, particularly because vitamin B12 deficiency can cause irreversible neurological damage. Early diagnosis and treatment are essential to prevent complications. The condition can affect people of all ages but is more common in older adults and individuals with malabsorption disorders.

Causes of Megaloblastic Anaemia

Megaloblastic anaemia can result from several causes:

• Vitamin B12 deficiency: Most commonly due to pernicious anaemia (autoimmune destruction of gastric parietal cells), which leads to a lack of intrinsic factor and impaired B12 absorption. Other causes include strict vegetarian or vegan diets, gastric surgery, and malabsorption disorders such as Crohn’s disease.
• Folic acid deficiency: Causes include inadequate dietary intake (poor diet, alcoholism), increased demand (pregnancy, haemolytic anaemia), or malabsorption (coeliac disease, inflammatory bowel disease).
• Drug-induced: Certain medications such as methotrexate, phenytoin, and sulfasalazine can interfere with folate metabolism.

Symptoms of Megaloblastic Anaemia

The symptoms of megaloblastic anaemia can be divided into haematological, gastrointestinal, and neurological manifestations:

• Haematological: Fatigue, weakness, paleness (pallor), shortness of breath, dizziness, and tachycardia (rapid heart rate).
• Gastrointestinal: Glossitis (inflamed tongue), angular cheilitis (cracked corners of the mouth), anorexia, diarrhoea, and weight loss.
• Neurological: Paraesthesia (tingling sensation in hands and feet), peripheral neuropathy, loss of proprioception (sense of position), difficulty walking, memory problems, cognitive impairment, and depression. Neurological symptoms can occur even in the absence of anaemia.

Diagnosis of Megaloblastic Anaemia

Diagnosis is based on clinical presentation and laboratory findings:

• Complete blood count (CBC): Shows macrocytic anaemia with elevated mean corpuscular volume (MCV).
• Peripheral blood smear: Shows hypersegmented neutrophils (with six or more lobes) and macro-ovalocytes (large oval red blood cells).
• Vitamin B12 and folate levels: Low serum vitamin B12 (< 200 pg/mL) or low red blood cell folate levels confirm the diagnosis.
• Additional tests for B12 deficiency: Serum methylmalonic acid and homocysteine levels are elevated in B12 deficiency, while homocysteine is elevated in folate deficiency.

Management of Megaloblastic Anaemia

Non-Pharmacological Management

Non-pharmacological interventions include:

• Dietary modification: Encouraging consumption of foods rich in vitamin B12 (meat, fish, dairy, eggs) and folate (dark leafy greens, citrus fruits, legumes, fortified cereals).
• Alcohol cessation: Alcohol interferes with folate absorption and should be avoided.
• Addressing underlying causes: Treating malabsorption disorders or adjusting medications that interfere with folate metabolism.

Pharmacological Management

Pharmacological treatment depends on the underlying deficiency:

• Vitamin B12 deficiency: Treatment options include oral vitamin B12 supplements (cyanocobalamin) or intramuscular injections. For patients with pernicious anaemia or severe deficiency, intramuscular injections of 1000 mcg of cyanocobalamin are given daily for one week, then weekly for one month, followed by monthly maintenance injections.
• Folic acid deficiency: Folic acid supplements (1 mg daily) are effective and well-tolerated. Higher doses may be required for patients with malabsorption or increased demand (pregnancy, haemolytic anaemia).
• Monitoring: Haemoglobin levels typically rise within 1-2 weeks of treatment. Response to therapy should be monitored with periodic blood counts.
• Important note: Treatment with folic acid alone in vitamin B12 deficiency can mask the anaemia but allow neurological damage to progress. Therefore, patients should be screened for B12 deficiency before starting folic acid therapy.

COMPARISON TABLE: IRON DEFICIENCY ANAEMIA VS MEGALOBLASTIC ANAEMIA

Feature	Iron Deficiency Anaemia	Megaloblastic Anaemia
Deficiency	Iron	Vitamin B12 or Folic Acid
Cell size	Microcytic (small)	Macrocytic (large)
MCV	Low (< 80 fL)	High (> 100 fL)
Common causes	Blood loss, poor diet, pregnancy	Pernicious anaemia, diet, malabsorption
Key symptoms	Fatigue, pallor, brittle nails	Fatigue, glossitis, tingling
Neurological symptoms	Rare	Common in B12 deficiency
Treatment	Oral/IV iron	Vitamin B12 or Folic acid
Diagnostic markers	Low ferritin, low serum iron	Low B12 or folate, high MCV

A TEACHER’S CLINICAL INSIGHTS

Over my years of teaching haematology and pharmacotherapeutics, I have developed a few key insights about haematological disorders that I always share with my students:

• Iron deficiency anaemia is a diagnosis, not a disease. Always investigate the underlying cause of iron deficiency, particularly in men and postmenopausal women where gastrointestinal bleeding is a concern.
• Vitamin B12 deficiency can cause irreversible neurological damage. Never assume that anaemia is the only manifestation. Neurological symptoms should be treated as a medical emergency.
• Oral iron supplements are the first-line treatment for IDA. However, they cause gastrointestinal side effects. Educate patients on how to minimize these side effects and emphasize adherence.
• Pernicious anaemia is an autoimmune condition that requires lifelong vitamin B12 replacement. Patients should be counseled about the importance of lifelong adherence to therapy.

FREQUENTLY ASKED QUESTIONS (FAQs)

1. What is iron deficiency anaemia?

Iron deficiency anaemia is a condition caused by a lack of iron in the body, leading to reduced haemoglobin production and impaired oxygen transport. It is the most common type of anaemia worldwide.

2. What causes megaloblastic anaemia?

Megaloblastic anaemia is caused by a deficiency of vitamin B12 or folic acid, which are essential for DNA synthesis and red blood cell production. Common causes include pernicious anaemia, poor diet, and malabsorption disorders.

3. What is the difference between iron deficiency anaemia and megaloblastic anaemia?

Iron deficiency anaemia is caused by iron deficiency and results in microcytic (small) red blood cells. Megaloblastic anaemia is caused by vitamin B12 or folate deficiency and results in macrocytic (large) red blood cells. The treatment and underlying causes are different.

4. How is iron deficiency anaemia treated?

Iron deficiency anaemia is treated with oral iron supplements (ferrous sulfate) and dietary modifications. In severe cases, intravenous iron may be required. Treatment should continue for 3-6 months to replenish iron stores.

5. What are the neurological symptoms of vitamin B12 deficiency?

Neurological symptoms of vitamin B12 deficiency include tingling and numbness in the hands and feet (paraesthesia), difficulty walking, loss of balance, memory problems, cognitive impairment, and depression. These can occur even without anaemia.

6. Why is vitamin C important for iron absorption?

Vitamin C (ascorbic acid) enhances the absorption of non-heme iron from plant sources by reducing ferric iron (Fe3+) to ferrous iron (Fe2+), which is more readily absorbed in the intestine.

7. Can megaloblastic anaemia be prevented?

Yes, megaloblastic anaemia can be prevented by maintaining a balanced diet rich in vitamin B12 (meat, fish, dairy) and folic acid (green leafy vegetables, citrus fruits, legumes). Supplementation is recommended during pregnancy and for individuals with malabsorption disorders.

SUMMARY

Haematological disorders like iron deficiency anaemia and megaloblastic anaemia require proper diagnosis and treatment through diet and pharmacotherapy to ensure effective patient care. Iron deficiency anaemia is caused by iron deficiency and is treated with oral iron supplements, dietary modifications, and addressing underlying causes of blood loss. Megaloblastic anaemia is caused by vitamin B12 or folic acid deficiency and requires supplementation, dietary improvements, and management of underlying conditions.

As healthcare professionals, we have a responsibility to educate patients about their conditions, recognize red flags, and ensure appropriate referral when needed. Early diagnosis and proper management of haematological disorders can significantly improve patient outcomes and quality of life.

As I always tell my students: “Anaemia is not a disease—it is a sign of something else. Finding the cause is as important as treating the symptom.”

REFERENCES AND FURTHER READING

• Kasper, D. L., Fauci, A. S., Hauser, S. L., et al. (2020). Harrison’s Principles of Internal Medicine (21st ed.). McGraw-Hill.
• Hoffman, R., Benz, E. J., Silberstein, L. E., et al. (2018). Hematology: Basic Principles and Practice (7th ed.). Elsevier.
• Bain, B. J., Bates, I., & Laffan, M. A. (2017). Practical Haematology (12th ed.). Wiley-Blackwell.
• National Institute for Health and Care Excellence (NICE). (2022). Clinical Guidelines on Anaemia. Retrieved from https://www.nice.org.uk.
• World Health Organization (WHO). (2022). Anaemia Resources. Retrieved from https://www.who.int.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare professionals for diagnosis and treatment.